Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes

Abstract

Purpose: Overactivation of TGF-b signaling is observed in myelodysplastic syndromes (MDS) and is associated with dysplastic hematopoietic differentiation. Galunisertib, a first-in-class oral inhibitor of the TGF-b receptor type 1 kinase (ALK5) has shown effectiveness in preclinical models of MDS and acceptable toxicity in phase I studies of solid malignancies.Patients and Methods: A phase II multicenter study of galunisertib was conducted in patients with very low-, low-, or intermediate-risk MDS by the Revised International Prognostic Scoring System criteria with hemoglobin 10.0 g/dL. Patients received oral galunisertib 150 mg twice daily for 14 days on/14 days off.Results: Ten of 41 evaluable patients (24.4%; 95% confidence interval, 12.4-40.3) achieved hematologic improvement erythroid response by International Working Group (IWG) 2006 criteria. A total of 18 of 41 patients (43.9%) achieved erythroid response as per IWG 2000 criteria. Nine of 28 (32.1%) of transfusion-dependent patients had hematologic improvement. A total of 18 of 41 (44%) patients had a significant reduction in fatigue. Overall median duration of response was 90 days in all patients. Rigorous stem and progenitor flow cytometry showed that patients with an early stem cell differentiation block were more likely to respond to galunisertib. The most common treatment-emergent adverse events were grade 1 or 2 in 20 (49%) of 41 patients, including any-grade fatigue (8/41, 20%), diarrhea (7/41, 17%), pyrexia (5/41, 12%), and vomiting (5/41, 12%).Conclusions: In summary, galunisertib treatment has an acceptable safety profile and was associated with hematologic improvements in lower-and intermediate-risk MDS, with responses in heavily transfusion-dependent patients and in those with signs of an early stem cell differentiation block.

Suppression of TGF-beta activity with remobilization attenuates immobilization-induced joint contracture in rats

“…It has also shown promising results in clinical trials due to its acceptable safety pro le. It produced a prolonged overall survival outcome in phase 1/2 trials for patients with hepatocellular carcinoma, myelodysplastic syndrome, and other neoplastic diseases [38][39][40][41][42].…”

RUNX1 haploinsufficiency causes a marked deficiency of megakaryocyte-biased hematopoietic progenitor cells: Mechanistic studies and drug correction

“…RS corrected the yield of Mks from both RUNX1 in CD41and CD41 + HPCs (Figure 7B), but did not affect erythroid or myeloid cells ( Figures 7C and 7D, respectively). Moreover, a different TGFβR1 inhibitor, Galunisertib (GS), in clinical development 72 , also corrected Mk yield ( Figure 7A).…”

Epithelial–mesenchymal transition: role in cancer progression and the perspectives of antitumor treatment

“…An inhibitor of the canonical Shh signaling pathway, the smoothened receptor inhibitor vismodegib, has been approved for the treatment of the most common form of skin cancer, basal cell carcinoma (metastatic and inoperable disease forms), or in cases of relapse after surgical treatment and radiotherapy [ 254 ]. Inhibitors of the PI3K/AKT/mTOR components of the EMT signaling pathway, cell cycle, and VEGF signaling have been approved for the treatment of kidney carcinoma (mTOR inhibitors temsirolimus and everolimus) [ 255 ], relapses of lymphoma resistant to other types of therapy, and chronic lymphocytic leukemia, in combination with rituximab (idelalisib, a PI3K inhibitor) [ 256 ]. Furthermore, a number of inhibitors are currently undergoing clinical trials, mainly in combination therapies.…”